Portland, OR -- (SBWIRE) -- 12/21/2017 -- Initially, no symptoms of the disease are observed, but when it further advances, bleeding, bone pain, frequent infections, and anemia may occur.

Increase in prevalence of blood cancer, rise in geriatric population, unhealthy lifestyle, growth in demand of biologic therapies, and emergence of nanomedicine drive the market. However, high cost of radiotherapeutic equipment and the chemotherapy process impede the growth of the market. In addition, increase in investments in R&D projects by government is expected to provide various opportunities for the market growth.

Access full summary at : https://www.alliedmarketresearch.com/multiple-myeloma-market

The global multiple myeloid market is segmented on the basis of therapeutics type and region. According to therapeutics type, the market is divided into chemotherapy and other drugs, radiation, and stem cell transplant and supportive treatments. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key players profiled in the report include Johnson & Johnson, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, Celegene Corporation, Amgen Inc., Innate Pharma SA, and Celldex Therapeutics, Inc.

Early buyers will receive 20% customization on this report
Get sample PDF brochure of this report: https://www.alliedmarketresearch.com/request-toc-and-sample/3725

Key Benefits

- The study provides an in-depth analysis of the market along with the current trends and future estimations to understand the imminent investment pockets.
- It presents a quantitative analysis from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.
- Extensive analysis of the market by type elucidates the regional trends.
- Key players and their strategies are analyzed to understand the competitive outlook of the market.